Pfizer Inc (PFE): Net Income
$7.77B
Year ended 2025-12-31
$4.33B
Trailing 12 months to 2026-06-28
-37.2%
3-year compound annual growth
-3.2%
5-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.77B | -3.2% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $8.03B | +279.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $2.12B | -93.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $31.37B | +42.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $21.98B | +140.0% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $9.16B | -42.8% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $16.03B | n/c | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $11.15B | -47.7% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $21.31B | +195.3% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $7.21B | +3.7% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $6.96B | -23.8% | 2018-02-22, From 2015-01-01 |
| 2014-12-31 | $9.13B | -58.5% | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | $22.00B | +51.0% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $14.57B | +45.6% | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | $10.01B | +21.2% | 2014-02-28, From 2011-01-01 |
| 2010-12-31 | $8.26B | -4.4% | 2013-02-28, From 2010-01-01 |
| 2009-12-31 | $8.63B | +6.6% | 2012-02-28, From 2009-01-01 |
| 2008-12-31 | $8.10B | -0.5% | 2011-02-28, From 2008-01-01 |
| 2007-12-31 | $8.14B | n/a | 2010-02-26, From 2007-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Pfizer Inc (PFE) | 2025-12-31 | $7.77B | -3.2% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $4.23B | -1.2% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $18.25B | +6.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $20.64B | +94.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $7.05B | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $6.52B | -51.3% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $26.80B | +90.6% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.41B | n/m |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.50B | +2.1% |
Compare PFE, ABBV, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗